NSAIDs cut risk of oral cancer among smokers

April 18, 2005

Anaheim, Calif. -- People who chose to light up cigarettes may want to take nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen as well, according to research reported here at the 96th Annual Meeting of the American Association for Cancer Research today.

"The use of NSAIDs among smokers protected against oral cancer development," said Jon Sudbø, M.D., Ph.D., D.D.S., a cancer researcher from the Norwegian Radium Hospital, Oslo, Norway, and lead author on the study.

People who took NSAIDs over extended periods of time and were light to moderate tobacco smokers had 65 percent less risk of developing oral cancer than smokers who went without NSAIDs, according to a population-based study on patients from the Norwegian Institute of Public Health and the Norwegian Cancer Registry.

"The results of a significant reduction in oral cancer risk - particularly in light to moderate active smokers - suggest that NSAID use may provide anti-carcinogenetic effect while the smokers are subjecting themselves to tobacco insult," Sudbø added.

The effect of the NSAIDs was best for those smokers who were considered 30 or less pack-year consumers of tobacco. A pack-year of smoking consists of averaging one pack of cigarettes per day per year. Those who smoke three packs per day for ten years, or two packs per day for 15 years are also considered 30 pack-year consumers. The effectiveness of NSAIDs diminished for smokers whose consumption was greater than 30 pack-year levels.

Sudbø and his colleagues in Norway and the United States analyzed health data on 908 individuals, half of whom had been diagnosed with squamous cell carcinoma of the oral cavity. They considered the use of six NSAIDs including aspirin, ibuprofen, naproxene, indomethacine, piroxicame, and ketoprofene, as well as acetaminophen. All types of NSAIDs were effective at reducing the rate of oral cancer.

Acetaminophen (paracetamol), a non-aspirin pain relief medication, was ineffective at reducing the risk of developing oral cancer among smokers.
-end-
Contributing to the study presented by Sudbø were J. Jack Lee and Scott M. Lippman, UT M. D. Anderson Cancer Center, Houston, Texas; Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, N.Y.; Simone Sagen, Wanja Kildal, and Albrecht Reith, The Norwegian Radium Hospital, Oslo, Norway; Jon Mork, The National Hospital, Oslo, Norway; Ari Ristimäki, Helsinki University Central Hospital, Helsinki, Finland; and Asle Sudbø, Norwegian University of Science and Technology, Trondheim, Norway.

Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meetings attract more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.

American Association for Cancer Research

Related Aspirin Articles from Brightsurf:

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

What are the risks and benefits of low-dose aspirin?
Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Study: An aspirin a day does not keep dementia at bay
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer's disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Aspirin's health benefits under scrutiny
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.

Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.

Migraine headaches? Consider aspirin for treatment and prevention
Evidence from 13 randomized trials of the treatment of migraine in 4,222 patients and tens of thousands of patients in prevention of recurrent attacks supports the use of high dose aspirin from 900 to 1,300 milligrams to treat acute migraine as well as low dose daily aspirin from 81 to 325 milligrams to prevent recurrent attacks.

Aspirin use after biliary tract cancer diagnosis
Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.

Aspirin may prevent air pollution harms
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function.

Aspirin should not be recommended for healthy people over 70
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease.

Read More: Aspirin News and Aspirin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.